Abstract: A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment.
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
November 21, 2023
Assignees:
HANGZHOU CONVERD CO., LTD.
Inventors:
Fang Hu, Yafei Hou, Jipo Sheng, Xiankui Tan
Abstract: Livestock animals and progeny thereof comprising at least one edited chromosomal sequence that alters expression or activity of a somatostatin receptor (SSTR) protein are provided. Livestock animal cells that contain such edited chromosomal sequences are also provided. The livestock animals have improved growth performance and weight gain. Methods for producing livestock animals with increased growth performance are also provided.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
October 24, 2023
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Jason Wayne Ross, Ronald Blythe Schultz, Nicholas Kurt Gabler
Abstract: A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.
Abstract: The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
October 10, 2023
Assignee:
UCL BUSINESS LTD
Inventors:
Stephanie Schorge, Matthew Charles Walker, Dimitri M. Kullmann, Albert Snowball, Elodie Chabrol
Abstract: A perfusion plate that can be combined with pillar plates containing cell layers is disclosed. The perfusion plate can have an inflow reservoir and an outflow reservoir connected by at least one channel, which fluidly connects the perfusion wells to the reservoirs for the flow of a fluid such as growth media. A perfusion plate can be part of an assembly containing a pillar plate, a lid, and a transparent bottom for visualizing cell growth in the perfusion wells. The perfusion-pillar plate assembly can facilitate perfusion-based tissue culture and tissue communication for high throughput, high-content, drug screening.
Abstract: Provided herein are, inter alia, methods useful for delivering nucleic acids and kinase inhibitors to a cell. The methods provided herein include the delivery of therapeutic nucleic acids to cancer cells by contacting a cancer cell with a kinase inhibitor and a therapeutic nucleic acid. The methods provided herein are therefore, inter alia, useful for the treatment of cancer.
Type:
Grant
Filed:
November 17, 2015
Date of Patent:
September 19, 2023
Assignee:
City of Hope
Inventors:
Cy Aaron Stein, Daniela Castanotto, David Horne
Abstract: The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.